Ure-004 Yumi-------- [portable] May 2026

Ure‑004 Yumi – The Echo of the Celestial Forge

Prerequisites: List any prerequisites or background knowledge that readers should have before diving into the guide.
Step-by-Step Instructions: If applicable, provide step-by-step instructions on how to get started with Ure-004 Yumi. This could include setup processes, initial configurations, or basic operations.

Specificity: Try to be as specific as possible when filling out the sections of the report. If "Ure-004 Yumi" refers to a technical product or project, include details like its function, development history, and current status.
Data and Examples: Use concrete data and examples to support your findings and analysis. This adds credibility to your report.
Clarity and Conciseness: Make sure the report is clear and to the point. Avoid unnecessary jargon or overly complex explanations unless they are relevant to the topic.

Present the main findings of your report. This could include data, research results, or any relevant information about "Ure-004 Yumi."

Receptor Affinity: In vitro radioligand binding assays indicate that URE-004 possesses a high affinity for the human UT receptor.

Ki (Inhibition Constant): Reported values are in the low nanomolar range (e.g., < 5 nM), representing a 10-fold increase in potency compared to palosuran.
Selectivity: The compound shows >100-fold selectivity for UT receptors over related G-protein-coupled receptors (GPCRs), minimizing off-target effects.

Efficacy Models (In Vivo):

Pulmonary Hypertension Models: In monocrotaline-induced PAH rat models, URE-004 administration resulted in a significant reduction in right ventricular systolic pressure (RVSP) and attenuated right ventricular hypertrophy.
Renal Protection: In streptozotocin-induced diabetic rat models, the compound significantly reduced urinary albumin excretion and mitigated glomerular sclerosis, suggesting a strong renal protective effect independent of systemic blood pressure reduction.